KLK5 and non-small cell lung carcinoma: Further Kaplan-Meier survival analysis suggested that low levels of serum KLK5 in NSCLC patients had a better response to anlotinib than those patients with a high level of serum KLK5 [Low (n = 11), Median PFS = 166 days vs. High (n = 17), Median PFS = 44 days, P = 0.008] (Figure 4B).